Effects of photodynamic therapy on tumor stroma

Ultrastructural Pathology

Volumn 28, Issue 5-6, 2004, Pages 333-340

  Peng, Qian ^a,b   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b FUDAN UNIVERSITY   (China)

Author keywords

Light irradiation; Microvasculature; Photodynamic therapy; Photosensitizer; Singlet oxygen; Tumor localization; Tumor stroma; Ultrastructural feature

Indexed keywords

CANCER RADIOTHERAPY; CONFERENCE PAPER; ENDOTHELIUM; IMMUNE RESPONSE; NONHUMAN; PARENCHYMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STROMA; TUMOR; TUMOR GROWTH; VASCULARIZATION;

ENDOTHELIUM, VASCULAR; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; STROMAL CELLS;

EID: 10644243468     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/01913120490515586     Document Type: Conference Paper

References (86)

1. Dougherty J, Gomer CJ, Henderson BW, et al. Review: photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905.
2. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991;53:549-553.
3. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol. 1996;20:109-129.
4. Spikes JD, Bommer JC. Zinc tetrasulphophthalocyanine as a photodynamic sensitizer for biomolecules. Int J Radiat Biol. 1986;50:41-45.
5. Girotti AW, Photodynamic lipid peroxidation in biological systems. Photochem Photobiol. 1990;51:497-509.
6. Agarwal ML, Clay ME, Harve EJ, Evans HH, Antunez AR, Oleinick NL. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. 1991;51:5993-5996.
7. Peng Q, Moan J, Nesland JM, Rimington C. Aluminum phthalocyanines with asymmetrical lower sulfonation and with symmetrical higher sulfonation: a comparison of localizing and photosensitizing mechanism in human tumor LOX xenografts. Int J Cancer. 1990;46:719-726.
8. Peng Q, Moan J, Warloe T, Nesland JM, Rimington C. Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in fmice bearing mammary carcinoma. Int J Cancer. 1992;52:433-443.
9. Peng Q, Moan J. Correlation of distribution of sulfonated aluminium phthalocyanine with their photodynamic effect in tumor and skin of mice bearing CaD2 mammary carcinoma. Br J Cancer. 1995;72:565-574.
10. Peng Q, Moan J, Ma LW, Nesland JM. Uptake, localization and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing CaD2 mammary carcinoma. Cancer Res. 1995;55:2620-2626.
11. Policard A, Leulier A. Caracterisation de l'haemato-porphyrine et de l'urobiline urinaire par la lumiere de wood and etude sur les aspects offerts par des tumour experimentales examinees a la lumiere de wood. C R Soc Biol. 1924;91:1422.
12. Peng Q, Nesland JM, Moan J, Evensen JF, Kongshaug M, Rimington C. Localization of fluorescent Photofrin II and aluminum phthalocyanine tetrasulfonate in transplanted human malignant tumor LOX and normal tissues of nude mice using highly light-sensitive video intensification microscopy. Int J Cancer. 1990;45:972-979.
13. Peng Q, Moan J, Farrants G, Danielsen HE, Rimington C. Localization of potent photosensitizers in human tumor LOX by means of laser scanning microscopy. Cancer Lett. 1991; 58:17-27.
14. Kongshaug M. Minireview: distribution of tetrapyrrole photosensitizers among human plasma proteins. Int J Biochem. 1992;24:1239-1265.
15. Kessel D, Woodburn K. Biodistribution of photosensitizing agents. Int J Biochem. 1993;25:1377-1383.
16. Kessel D, Thompson P, Saatio K, Nantwi KD. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine. Photochem Photobiol. 1987;45:787-790.
17. Chang CT, Dougherty TJ. Photoradiation therapy: kinetics and thermodynamics of porphyrin uptake and loss in normal and malignant cells in culture. Radiat Res. 1978;74:498.
18. Moan J, Steen HB, Feren K, Christensen T. Uptake of hematoporphyrin derivative and sensitized photoinactivation of C3H cells with different oncogenic potential. Cancer Lett. 1981;14:291-296.
19. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039-3051.
20. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6:559-594.
21. Gullino PM. Extracellular compartments of solid tumors. In: Becker FF, ed. Cancer, A Comprehensive Treatise., Vol. 3: Biology of Tumors. New York: Plenum Press; 1975: 327-354.
22. Eccles S, Alexander P. Macrophages content of tumors in relation to metastatic spread and host immune reaction. Nature. 1974;250:667-669.
23. Wike-Hooley L, Haveman J, Reinhold HS. The relevance of tumor pH to the tretament of malignant disease. Radiother Oncol. 1984;2:343-366.
24. Thomas JP, Girotti AW. Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. Photochem Photobiol. 1989;49:241-247.
25. Brault D. Physical chemistry of porphyrins and their interaction with membranes: the importance of pH. J Photochem Photobiol. 1990;6:79-86.
26. Peng Q, Moan J, Cheng LS. The effect of glucose administration on the uptake of Photofrin Il in a human tumor xenograft. Cancer Lett. 1991;58:29-35.
27. Gal D, McDonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. III: low density lipoprotein metabolism. Int J Cancer. 1981;29:315-319.
28. Norata G, Canti G, Ricci L, Nicolin A, Trezzi E, Catapona AL. In vivo assimilation of low density lipoproteins by a fibrosarcoma tumor line in mice. Cancer Lett. 1984;25:203-208.
29. Roberts WG, Hasan T. Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Cancer Res. 1993;53:153-157.
30. Sakakibara K, Suzuki T, Motoyama T, Watanabe H, Nagai Y. Biosynthesis of an interstitial type of collagen by cloned human gastric carcinoma cells. Cancer Res. 1982; 42:2019-2027.
31. Al-Adnani MS, Kirrane JA, McGee JO. Inappropriate production of collagen and prolyhydroxylase by human breast cancer cells in vivo. Br J Cancer. 1975;31:653-660.
32. Musser DA, Wagner JM, Weber FJ, Datta-Gupta N. The effect of tumor localizing porphyrins on the conversion of fibrinogen to fibrin. Res Commun Chem Pathol Pharmacol. 1979; 26:357-382.
33. Musser DA, Wagner JM, Weber FJ, Datta-Gupta N. The binding of tumor localizing porphyrins to a fibrin matrix and their effects following photoirradiation. Res Commun Chem Pathol Pharmacol. 1980;28:505-525.
34. Musser DA, Wagner JM, Datta-Gupta N. The interaction of tumor localizing porphyrins with collagen and elastin. Res Commun Chem Pathol Pharmacol. 1982;36:251-259.
35. El-Far MA, Pimstone NR. The interaction of tumor-localizing porphyrins with collagen, elastin, gelatin, fibrin and fibrinogen. Cell Biochem Function. 1985;3:115-119.
36. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin, IX: basic principle and present clinical experience. J Photochem Photobiol B:Biol. 1990;6:143-148.
37. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997; 65:235-251.
38. Peng, Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer. 1997;79:282-308.
39. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjørseth A, Nesland JM. Build-up of esterified ALA derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B:Biol. 1996;34:95-96.
40. Kloek J, Beijersbergen van Henegouwen GMJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol. 1996;64:994-1000.
41. Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57:1481-1486.
42. Kloek J, Akkermans W, Beijersbergen van Henegouwen MJ. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol. 1998;67:150-154.
43. Tunstall RG, Barnett AA, Schofield J, et al. Porphyrin accumulation induced by 5-aminolevulinic acid esters in tumor cells growing in vitro and in vivo. Br J Cancer. 2002;87:246-250.
44. Kennedy JC, Ringuet M, Pottier RH. Protease mediated drug delivery system. U.S. Patent No. 5,618,790: 1997.
45. Selman SH, Keck RW, Klauning JE, Kreimer-Birnbaum M, Goldblatt PJ, Britton SL. Acute blood flow changes in transplantable FANFT-induced urothelial tumors treated with hematoporphyrin derivative and light. Surg Forum. 1983;34:676-678.
46. Star WM, Marijnissen HPA, van den Berg-Blok AE, Versteeg JAC, Franken KAP, Reinhold HS. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986;46:2532-2540.
47. Chandhuri K, Keck RW, Selman S. Morphological changes of tumor microvasculature following hematoporphyrin derivative sensitizer photodynamic therapy. Photochem Photobiol. 1987;46:823-827.
48. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 1992;52:4914-4921.
49. Reed MWR, Wieman TJ, Doak KW, Pietsch K, Schuschke DA. The microvascular effects of photodynamic therapy: evidence for a possible role of cyclooxigenase products. Photochem Photobiol. 1989;50:419-423.
50. Kerdel FA, Soter NA, Lim HW. In vivo mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. J Invest Dermatol. 1987;88:277-280.
51. Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA. Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res. 1991;51:3261-3266.
52. Ris HB, Altermatt HJ, Inderbitzi R, et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer. 1991;64:1116-1120.
53. Henderson BW. Probing the effects of photodynamic therapy through in vivo-in vitro methods. In: Kessel D, ed. Photodynamic Therapy of Neoplastic Disease. Vol. I. Boca Raton, FL.: CRC Press; 1990:169-188.
54. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthalocyanine. J Natl Cancer Inst. 1988;80:1599-1605.
55. Peng Q, Warloe T, Moan J, et al. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of Photofrin in human tumor xenografts. Cancer Res. 2001; 61:5824-5832.
56. Ferrario A, von Tiehl K, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066-4069.
57. Ferrario A, von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002;62:3956-3961.
58. Nelson JS, Wright WH, Berns MW. Comparison of fluorescence and photodynamic activities of whole hematoporphyrin derivative and its enriched active components. J Natl Cancer Inst. 1985;75:1135-1140.
59. Dolmans DEJGJ, Kadambi A, Hill JS, et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res. 2002;62:4289-4294.
60. Bergers G, Coussens LM. Extrinsic regulations of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev. 2000;10:120-127.
61. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
62. Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human, dermal fibroblasts. J Invest Dermatol. 2003;120:325-331.
63. Ferrario A, Chantrain CF, von Tiehl K, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 2004;64:2328-2332.
64. Gomer CJ, Ferrario A, Murphree A. The effect of localized porphyrin photodynamic therapy on the induction of tumor metastasis. Br J Cancer. 1987;56:27-32.
65. Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 1998;58:5425-5431.
66. Margaron P, Sorrenti R, Levy JG. Photodynamic therapy inhibits cell adhesion without altering integrin expression. Biochim Biophys Acta. 1997;1359:200-210.
67. Haylett AK, Higley K, Chiu M, Shackley DC, Moore JV. Collagen secretion after photodynamic therapy versus scar-inducing anti-cancer modalities: an in vitro study. Photochem Photobiol Sci. 2002;1:673-677.
68. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg. 1996;14:329-334.
69. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid population in the response of mouse EMT-6 tumor to photodynamic therapy. Cancer Res. 1996;56:5647-5652.
70. de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 1996;56:2908-2911.
71. van Duijnhoven FH, Aalbers RIJM, Rovers JP, Terpstra OT, Kuppen PJK. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003;207:105-113.
72. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002;62:1604-1608.
73. Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res. 1996;56:3281-3286.
74. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer. 1997;75:202-207.
75. Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res. 2004;10:4498-4508.
76. Marshall JF, Chan WS, Hart IR. Effect of photodynamic therapy on anti-tumor immune defenses: comparison of the photosensitizers hematoporphyrin derivative and chloro-aluminum sulfonated phthalocyanine. Photochem Photobiol. 1989;49:627-632.
77. Jolies C, Ott MJ, Straight RC, Lynch DH. Systemic immunosuppression induced by peritoneal photodynamic therapy. Am J Obstet Gynecol. 1988;158:1446-1453.
78. Musser DA, Fiel RJ. Cutaneous photosensitizing and immunosuppressive effects of a series of tumor localizing porphyrins. Photochem Photobiol. 1991; 53:119-123.
79. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 1997;57:3904-3909.
80. Simkin GO, Tao JS, Levy JG, Hunt DW. IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy. J Immunol. 2000;164:2457-2462.
81. Obochi MO, Ratkay LG, Levy JG. Prolonged skin allograft survival after photodynamic therapy associated with modification of donor skin antigenicity. Transplantation. 1997;63:810-817.
82. Moan J, Peng Q. An outline of history of photodynamic therapy. Anticancer Res. 2003;23:3591-3600.
83. Demidova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol. 2004;17:117-126.
84. Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg. 1996;14:343-348.
85. Hayase M, Woodburn KW, Perlroth J, et al. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc Res. 2001;49:449-455.
86. Chou TM, Woodburn KW, Cheong WF, et al. Photodynamic therapy: application in atherosclerotic vascular disease with motexafin lutetium. Cathet Cardiovasc Intervent. 2002;57:387-394.